Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15136756 | 1.00 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL528017 | 1.00 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL528016 | 1.00 | KDM1A (1.00) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL15136201 | 0.99 | KDM1A (0.97) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL15136202 | 0.99 | KDM1A (0.97) | KDM1AMAOB | |
| SCHEMBL526723 | 0.87 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL527740 | 0.87 | KDM1A (1.00) | KDM1AMAOB | |
| SCHEMBL527741 | 0.87 | KDM1A (1.00) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL527302 | 0.86 | KDM1A (0.97) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL15137073 | 0.86 | KDM1A (0.97) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676701-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2017-06-13 | — | — | US | disclosed |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAOB 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.